DAVID LAZZARO: Open Payments
NPI 1508589789 · SCHENECTADY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,966 in 64 payments from 17 companies in 2025. Trend: 2023 $426 · 2024 $913 · 2025 $1,966
Food & beverage: $1,867Education: $99
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 11 | $399 |
| Astellas Pharma US Inc | 8 | $375 |
| Sumitomo Pharma America, Inc. | 8 | $172 |
| Ferring Pharmaceuticals Inc. | 6 | $163 |
| Merck Sharp & Dohme LLC | 5 | $115 |
| Endo USA, Inc. | 5 | $113 |
| TOLMAR, INC. | 6 | $104 |
| Boston Scientific Corporation | 1 | $101 |
| COLOPLAST CORP | 1 | $100 |
| PFIZER INC. | 4 | $73 |
Products named: XTANDI, ERLEADA, GEMTESA, ADSTILADRIN, LYNPARZA, RYBREVANT, AMS 700, Luja Coude.
Industry payments across NY — which companies pay providers there.
